Subcutaneous Benlysta regulatory update

GlaxoSmithKline submitted an NDA in Japan for IV and subcutaneous Benlysta belimumab to treat active, autoantibody-positive systemic lupus erythematosus (SLE) in adults who have an inadequate response...